[go: up one dir, main page]

MX2017012407A - Celulas t modificadas y métodos para hacer y usar las mismas. - Google Patents

Celulas t modificadas y métodos para hacer y usar las mismas.

Info

Publication number
MX2017012407A
MX2017012407A MX2017012407A MX2017012407A MX2017012407A MX 2017012407 A MX2017012407 A MX 2017012407A MX 2017012407 A MX2017012407 A MX 2017012407A MX 2017012407 A MX2017012407 A MX 2017012407A MX 2017012407 A MX2017012407 A MX 2017012407A
Authority
MX
Mexico
Prior art keywords
cells
methods
administered
modified
make
Prior art date
Application number
MX2017012407A
Other languages
English (en)
Inventor
b meissner Torsten
Y Mulumba Kabungo
M R Ferreira Leonardo
A Cowan Chad
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2017012407A publication Critical patent/MX2017012407A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

En el presente documento se describen células T humanas primarias modificadas y poblaciones de las mismas, que comprenden un genoma en el cual los genes CTLA4, PD1, TCRA, TCRB, y/o B2M han sido editados para generar una célula CAR-T universal de disponible de donantes sanos orogénicos que se puede administrar a cualquier paciente mientras reduce o elimina el riesgo de rechazo inmunológico o enfermedad de injerto contra hospedero y que no son propensos a la inhibición de las células T, y métodos para la administración alogénica de esa células para reducir la probabilidad de que las células activen una respuesta inmunitaria del hospedero cuando las células se administran a un sujeto que necesita esas células.
MX2017012407A 2015-03-27 2016-03-28 Celulas t modificadas y métodos para hacer y usar las mismas. MX2017012407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562139479P 2015-03-27 2015-03-27
PCT/US2016/024554 WO2016160721A1 (en) 2015-03-27 2016-03-28 Modified t cells and methods of making and using the same

Publications (1)

Publication Number Publication Date
MX2017012407A true MX2017012407A (es) 2018-03-07

Family

ID=57007260

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012407A MX2017012407A (es) 2015-03-27 2016-03-28 Celulas t modificadas y métodos para hacer y usar las mismas.
MX2024006041A MX2024006041A (es) 2015-03-27 2017-09-27 Celulas t modificadas y metodos para hacer y usar las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024006041A MX2024006041A (es) 2015-03-27 2017-09-27 Celulas t modificadas y metodos para hacer y usar las mismas.

Country Status (11)

Country Link
US (3) US20160348073A1 (es)
EP (2) EP4269601A3 (es)
JP (4) JP2018510657A (es)
KR (1) KR20180020125A (es)
CN (2) CN115537396A (es)
AU (3) AU2016243583B2 (es)
BR (1) BR112017020750A2 (es)
CA (1) CA2984237A1 (es)
IL (2) IL302341A (es)
MX (2) MX2017012407A (es)
WO (1) WO2016160721A1 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
ES3033286T3 (en) * 2014-03-05 2025-08-01 Autolus Ltd Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
CN107206024B (zh) * 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
EP3215623A4 (en) * 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
RU2734770C2 (ru) 2014-11-21 2020-10-23 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк
EP4269601A3 (en) * 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
AU2016261600B2 (en) 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
US11643668B2 (en) 2015-06-17 2023-05-09 The Uab Research Foundation CRISPR/Cas9 complex for genomic editing
WO2016205680A1 (en) * 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
EP4545544A3 (en) 2015-06-29 2025-10-08 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP6974681B2 (ja) * 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
US11242375B2 (en) 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN108601821B (zh) 2015-10-05 2023-09-19 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
CA3001008A1 (en) 2015-10-05 2017-04-13 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
HK1257295A1 (zh) * 2015-12-04 2019-10-18 Novartis Ag 用於免疫肿瘤学的组合物和方法
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
KR20240173370A (ko) * 2016-03-04 2024-12-11 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
PT4180519T (pt) 2016-04-15 2025-09-04 Memorial Sloan Kettering Cancer Center Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados
EP4368637A3 (en) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
AU2017319151B2 (en) * 2016-08-30 2024-01-11 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
JP7236380B2 (ja) * 2016-10-19 2023-03-09 セレクティス 治療に適したｔａｌエフェクターヌクレアーゼ（ｔａｌｅｎ）改変同種異系細胞
AU2017347637B2 (en) * 2016-10-19 2024-02-15 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
US12269859B2 (en) 2016-12-02 2025-04-08 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
CA3054556A1 (en) 2017-02-23 2018-08-30 DePuy Synthes Products, Inc. Aneurysm device and delivery system
WO2018162696A1 (en) * 2017-03-10 2018-09-13 Institut Pasteur Common genetic variations at the tcra-tcrd locus control thymic function in humans
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
PT3592379T (pt) * 2017-03-31 2024-05-31 Cellectis Sa Células imunitárias manipuladas universais dotadas de recetor antigénico quimérico anti-cd22
AU2018248961B2 (en) * 2017-04-07 2024-06-20 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
US10934336B2 (en) 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
CN110621333A (zh) * 2017-05-08 2019-12-27 荷兰联合利华有限公司 炎性皮肤病的预防和/或治疗
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
WO2018215779A1 (en) 2017-05-25 2018-11-29 Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences Methods for increasing grain productivity
EP3650545A4 (en) * 2017-06-20 2021-03-31 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TARGETING A TARGET CELL IN VITRO AND CRRNA USED IN THIS METHOD
SG10201705285SA (en) * 2017-06-27 2019-01-30 Agency Science Tech & Res Antisense oligonucleotides
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
WO2019005957A1 (en) * 2017-06-30 2019-01-03 Precision Biosciences, Inc. GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE
CN118853394A (zh) * 2017-07-18 2024-10-29 阿维塔斯有限公司 使用连续流动的流体系统进行跨细胞膜的有效装载的传递
US20200216805A1 (en) * 2017-09-18 2020-07-09 Edigene Inc. Gene editing t cell and use thereof
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
US12397038B2 (en) 2017-11-29 2025-08-26 Uti Limited Partnership Ubiquitous antigens for treatment of autoimmune or inflammatory diseases
US20210002621A1 (en) * 2017-12-20 2021-01-07 Bluebird Bio, Inc. Ctla4 homing endonuclease variants, compositions, and methods of use
CN111788307A (zh) * 2018-03-12 2020-10-16 南京北恒生物科技有限公司 工程化的嵌合向导rna及其用途
EP3765040A4 (en) * 2018-03-13 2021-12-01 Regents of the University of Minnesota LYMPHOHEMATOPOIETIC MANIPULATION USING CAS9 BASE EDITORS
EP3781196B1 (en) 2018-03-27 2024-03-06 G+Flas Life Sciences Sequence-specific in vivo cell targeting
US11865164B2 (en) * 2018-03-27 2024-01-09 G+Flas Life Sciences Pharmaceutical composition for treating cancer, containing guide RNA and endonuclease as active ingredients
WO2019195491A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
WO2019200122A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
BR112020014803A2 (pt) * 2018-04-13 2020-12-08 Sigma-Aldrich Co. Llc Modificação de loci genômicos relacionados ao sistema imune usando ribonucleoproteínas crispr nickases emparelhadas
US20190247437A1 (en) * 2018-04-19 2019-08-15 APDN (B.V.I.), Inc. Engineered lymphocyte compositions, methods and systems
SG11202011080QA (en) 2018-05-11 2020-12-30 Crispr Therapeutics Ag Methods and compositions for treating cancer
EP3801574A4 (en) * 2018-05-31 2022-03-16 Washington University METHODS FOR GENOMIC EDITING AND CELL ACTIVATION
WO2019237394A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种应用CRISPR/Cas9系统靶向敲除人ALPS5基因的方法
WO2019237381A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 用于人alps5基因编辑的修饰载体、其制备方法及应用
CN112654245B (zh) * 2018-09-11 2022-05-27 得克萨斯州大学系统董事会 自身免疫不良事件和免疫检查点阻断治疗的遗传小鼠模型
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20210091160A (ko) * 2018-10-16 2021-07-21 인텔리아 테라퓨틱스, 인크. 면역요법을 위한 조성물 및 방법
CN113573740A (zh) 2018-11-09 2021-10-29 利兰斯坦福初级大学董事会 用于核酸递送的混合分解细胞穿透复合物
CN109652378B (zh) * 2018-12-29 2020-04-24 广州百暨基因科技有限公司 一种功能增强的通用型car-t细胞及其制备方法和用途
JP6884450B2 (ja) * 2019-02-14 2021-06-09 学校法人獨協学園獨協医科大学 Ｔ細胞ワクチン
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3981431A4 (en) * 2019-03-14 2023-06-28 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
JP2022531185A (ja) 2019-04-30 2022-07-06 クリスパー セラピューティクス アクチェンゲゼルシャフト 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3997221A4 (en) * 2019-07-08 2023-07-05 Inscripta, Inc. INCREASED NUCLEIC ACID-DRIVEN CELL EDIT VIA A LEXA-RAD51 FUSION PROTEIN
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN110863015B (zh) * 2019-11-25 2023-06-16 重庆精准生物产业技术研究院有限公司 对t细胞低敏感性的靶细胞及其制备方法和应用
WO2021119006A1 (en) * 2019-12-09 2021-06-17 Caribou Biosciences, Inc. Crispr abasic restricted nucleotides and crispr accuracy via analogs
TW202140784A (zh) 2020-01-17 2021-11-01 美商薩那生物科技公司 用於調節基因表現的安全開關
WO2021158918A1 (en) * 2020-02-05 2021-08-12 Danmarks Tekniske Universitet Compositions and methods for targeting, editing or modifying human genes
EP4114952A4 (en) * 2020-03-05 2024-05-08 Board of Regents of the University of Nebraska Crispr/cas9 system for multistrain hiv-1 treatment
IL296321A (en) * 2020-03-13 2022-11-01 Univ California Preparations and methods for modifying a designated nucleic acid
US20230374454A1 (en) * 2020-04-06 2023-11-23 Synthekine, Inc. Human immune cells genomically modified to express orthogonal receptors
IL299288A (en) * 2020-06-26 2023-02-01 Carisma Therapeutics Inc Transfection of mRNA in immune cells
KR20220005208A (ko) * 2020-07-06 2022-01-13 주식회사 지씨셀 면역원성이 감소된 신규한 이식용 세포
EP4196568A1 (en) 2020-08-13 2023-06-21 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
WO2022094329A1 (en) * 2020-10-30 2022-05-05 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting pdcd1 and uses thereof
KR20230093328A (ko) * 2020-10-30 2023-06-27 아버 바이오테크놀로지스, 인크. B2m을 표적화하는 rna 가이드를 포함하는 조성물 및 이의 용도
US20240026351A1 (en) * 2020-10-30 2024-01-25 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
US20240042025A1 (en) * 2020-12-14 2024-02-08 Emendobio Inc. Biallelic knockout of b2m
US11965022B2 (en) 2020-12-31 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
BR112023019195A2 (pt) * 2021-03-24 2023-10-17 Genentech Inc Edição eficiente do gene tcr em linfócitos t
US20220315931A1 (en) * 2021-03-26 2022-10-06 A2 Biotherapeutics, Inc. Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin gene
WO2022246293A1 (en) 2021-05-19 2022-11-24 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
IL308097A (en) 2021-05-27 2023-12-01 Sana Biotechnology Inc Hypoimmunogenic cells comprising engineered hla-e or hla-g
US20240293543A1 (en) * 2021-06-23 2024-09-05 Editas Medicine, Inc. Engineered cells for therapy
AU2022309875A1 (en) 2021-07-14 2024-01-25 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
MX2024001208A (es) 2021-08-11 2024-04-22 Sana Biotechnology Inc Celulas primarias geneticamente modificadas para terapia celular alogenica.
JP2024532772A (ja) 2021-08-11 2024-09-10 サナ バイオテクノロジー，インコーポレイテッド 低免疫原性細胞における遺伝子発現を変化させるための誘導性システム
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024533940A (ja) 2021-08-27 2024-09-18 メタゲノミ，インク． Ｒｕｖｃドメインを有する酵素
WO2023034276A2 (en) * 2021-09-02 2023-03-09 The Regents Of The University Of California Materials and methods for targeted genetic manipulations in cells
GB202112922D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Method
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
MX2024007790A (es) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.
AU2022422147A1 (en) 2021-12-23 2024-07-04 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023225670A2 (en) * 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023250490A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of trac expression
WO2024088401A1 (en) * 2022-10-28 2024-05-02 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
KR20250161527A (ko) * 2023-01-13 2025-11-17 레이버락 테라퓨틱스 리미티드 억제 rna를 이용한 세포 맥락 특이적 유전자 조절
WO2025096757A1 (en) 2023-11-01 2025-05-08 Sana Biotechnology, Inc. Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5130300A (en) 1986-03-07 1992-07-14 Monsanto Company Method for enhancing growth of mammary parenchyma
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ATE113059T1 (de) 1987-06-24 1994-11-15 Florey Howard Inst Nukleosid-derivate.
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション オリゴヌクレオチド　ｎ‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
AU658562B2 (en) 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
DE69126530T2 (de) 1990-07-27 1998-02-05 Isis Pharmaceutical, Inc., Carlsbad, Calif. Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
KR100211552B1 (ko) 1990-08-03 1999-08-02 디. 꼬쉬 유전자 발현 억제용 화합물 및 방법
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
GB9100304D0 (en) 1991-01-08 1991-02-20 Ici Plc Compound
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
EP0618925B2 (en) 1991-12-24 2012-04-18 Isis Pharmaceuticals, Inc. Antisense oligonucleotides
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
DE4203923A1 (de) 1992-02-11 1993-08-12 Henkel Kgaa Verfahren zur herstellung von polycarboxylaten auf polysaccharid-basis
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
DK0691968T3 (da) 1993-03-30 1998-02-23 Sanofi Sa Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse
JPH08508491A (ja) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
EP0729474A4 (en) 1993-11-16 1998-10-21 Genta Inc SYNTHETIC OLIGOMERS THAT HAVE CHIRALITY-PURE PHOSPHONATE INTERNUCLEOSIDYL BINDINGS MIXED WITH NON-PHOSPHONATE INTERNUKLEOSIDYL BINDINGS
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US5645620A (en) 1995-05-25 1997-07-08 Foster Wheeler Development Corp. System for separating particulates and condensable species from a gas stream
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
US6875904B2 (en) * 2000-09-20 2005-04-05 The Ohio State University Research Foundation Animal model for identifying agents that inhibit or enhance CTLA4 signaling
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
JP2004537311A (ja) 2001-07-16 2004-12-16 プライス ファンデーション リミテッド 摂食障害に関連する遺伝子およびｓｎｐ
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US8409861B2 (en) * 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
KR100590547B1 (ko) 2004-02-28 2006-06-19 삼성전자주식회사 복합 질환과 연관된 다중 ｓｎｐ 마커들로부터 최적 마커세트를 선택하는 방법
US20080268436A1 (en) 2004-08-20 2008-10-30 Jubao Duan Schizophrenia, Schizoaffective Disorder and Bipolar Disorder Susceptibility Gene Mutation and Applications to Their Diagnosis and Treatment
US20060204969A1 (en) 2005-01-14 2006-09-14 Hoffman Eric P Genetic variations (SNPs) adjacent to the AKT1 gene locus, and diagnostic and prognostic uses thereof
KR101206029B1 (ko) 2005-04-01 2012-11-28 삼성전자주식회사 대장암 진단용 다중 ｓｎｐ, 그를 포함하는 마이크로어레이및 키트 및 그를 이용한 대장암 진단 방법
EP1883711A4 (en) 2005-05-18 2009-07-15 Samsung Electronics Co Ltd METHOD AND USES FOR DIAGNOSIS OF A HEART CIRCULATION DISEASE
US20070269827A1 (en) 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
US20080199866A1 (en) 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
EP2198049A1 (en) 2007-09-10 2010-06-23 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on snp genotype
US8563314B2 (en) * 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
CA2718392A1 (en) 2008-03-14 2009-09-17 Genoscreen Biomarkers for alzheimer's disease
CA2749869A1 (en) 2009-03-03 2010-09-10 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
US8445656B2 (en) 2009-08-11 2013-05-21 University Of Guelph Single nucleotide polymorphisms (SNPs) in genes associated with inflammatory diseases
AU2010301042B2 (en) 2009-10-01 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011065982A2 (en) 2009-11-30 2011-06-03 23Andme, Inc. Polymorphisms associated with parkinson's disease
CN102918158B (zh) 2010-05-31 2014-05-28 山东大学 与多囊卵巢综合征相关的snp、包含snp的芯片及其应用
ES2387292B1 (es) 2010-06-29 2013-10-30 Fundacio Institut De Recerca Hospital Universitari Vall D'hebron Combinacion de snps para determinar el riesgo de sufrir una enfermedad neurovascular
CA3179835A1 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
PT2535424E (pt) 2011-06-16 2015-10-29 Gendiag Exe Sl Snps associados a doença tromboembólica
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
HUE064187T2 (hu) * 2012-05-25 2024-02-28 Cellectis Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására
US9937207B2 (en) * 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
CA3185368A1 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t cells derived from pluripotent stem cells
CN105378067A (zh) * 2013-05-13 2016-03-02 塞勒克提斯公司 工程化用于免疫治疗的高活性t细胞的方法
AU2014273490B2 (en) * 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
JP6793902B2 (ja) * 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
KR102827558B1 (ko) * 2014-04-18 2025-07-11 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
GB201418965D0 (es) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
CN107206024B (zh) * 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
EP3215623A4 (en) * 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EP4269601A3 (en) * 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
AU2016261600B2 (en) * 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods

Also Published As

Publication number Publication date
IL254734B2 (en) 2023-09-01
AU2016243583A1 (en) 2017-11-16
IL254734B1 (en) 2023-05-01
AU2022203963A1 (en) 2022-06-23
HK1250481A1 (en) 2018-12-21
CN107847524A (zh) 2018-03-27
JP2023129663A (ja) 2023-09-14
JP2018510657A (ja) 2018-04-19
EP4269601A3 (en) 2024-01-10
US20160348073A1 (en) 2016-12-01
WO2016160721A1 (en) 2016-10-06
IL302341A (en) 2023-06-01
BR112017020750A2 (pt) 2018-06-26
US20220162554A1 (en) 2022-05-26
JP2021137036A (ja) 2021-09-16
IL254734A0 (en) 2017-11-30
JP2025181962A (ja) 2025-12-11
AU2022203963B2 (en) 2025-08-14
EP3273976A1 (en) 2018-01-31
AU2025210797A1 (en) 2025-08-21
US20220162555A1 (en) 2022-05-26
CA2984237A1 (en) 2016-10-06
KR20180020125A (ko) 2018-02-27
MX2024006041A (es) 2024-06-04
AU2016243583B2 (en) 2022-03-10
CN115537396A (zh) 2022-12-30
EP4269601A2 (en) 2023-11-01
EP3273976A4 (en) 2018-12-19
EP3273976B1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
MX2017012407A (es) Celulas t modificadas y métodos para hacer y usar las mismas.
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
CO2019011450A2 (es) Expresión transgénica selectiva de tejidos
MX2021005187A (es) Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
MX2018010924A (es) Células efectoras inmunitarias con edición genómica.
JP2016513460A5 (es)
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
MX2016009807A (es) Polipéptidos que administran epítopos de cmh de clase i.
CL2017001823A1 (es) Compuestos para mejorar el empalme de marn
MX384175B (es) Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva.
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
BR112017014345A2 (pt) populações de células do rpe e métodos de gerar as mesmas
EP3799871A3 (en) Pyrazol-3-ones that activate pro-apototic bax
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX2018003411A (es) Terapia glucodirigida.
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
MX2017014075A (es) Composiciones de peptido y metodos de uso.
AR104598A1 (es) Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
MX386476B (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
AR106351A1 (es) Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
Ani et al. Morphology of sella turcica in skeletal class II subjects
MX2021003798A (es) Terapia con celulas de placenta humana y celulas hematopoyeticas.